Tokyo, Dec 18, 2008 (JCN) - Takara Bio Inc. entered into a material transfer agreement with University of California at Los Angeles (UCLA) as of December 1st to supply Takara Bio's RetroNectin for use in a Phase II clinical trial of advanced melanoma conducted by the group of Dr. Antoni Ribas. Twenty-two patients are expected to be enrolled in this trial.
In the UCLA clinical trial, peripheral blood mononuclear cells (PBMCs) collected from melanoma patients are retrovirally-transduced in vitro utilizing the RetroNectin method with a gene encoding T-cell receptor (TCR) which specifically recognizes tumor antigen MART-1 expressing on melanoma cells.
The TCR-gene transduced PBMCs will be expanded in vitro and then infused back into the patients, so that the transduced PBMCs can specifically recognize and attack the tumor cells in the patients.
Under the protocol, patients will also receive autologous dendritic cells (DC) processed ex vivo in addition to the TCR-gene transduced PBMCs, that are expected to enable enhancement of patients' immunity to attack the melanoma cells.
This is the 44th clinical trial in which the RetroNectin method has been used. Currently, ex vivo gene therapy is expanding throughout the world as an effective method for several incurable diseases.
Copyright © 2013 JCN. All rights reserved. A division of Japan Corporate News Network KK.
 Company Profile |  Print |  Alerts
|
 |
|
Takara Bio Initiates Phase 1 HIV Gene Therapy Clinical Trial
(Jan 7, 2013)
|
|
|
Takara Bio Submits IND Application for HIV-1 Gene Therapy to the FDA
(Mar 23, 2012)
|
|
|
Takara Bio and Tianjin Medical University in Gene Therapy Project
(Aug 3, 2011)
|
|
|
Takara Bio RetroNectin to UCLA for TCR-gene Therapy Clinical Trials in Advanced Melanoma
(Dec 18, 2008)
|
|
|
Takara Bio Announces Start of Clinical Research of Cancer Immunotherapy using RetroNectin(R) Expansion Culture System at Tianjin Cancer Institute & Hospital, China
(May 2, 2008)
|
|
|
Takara Bio Grants Transgenomic License for LA-PCR Technology
(May 7, 2007)
|
|
|
ViroMed Obtains Clinical Trial Approval of Gene Therapy Treatment for Chronic Granulomatosis
(Jan 11, 2007)
|
|
|
Takara Bio's RetroNect Used in Australia for Gene Therapy Clinical Trials of Multiple Myeloma
(Dec 18, 2006)
|
|
|
Takara Bio Offers Drug for Treatment of Chronic Lymphatic Leukemia
(Sept 7, 2006)
|
|
|
Takara Bio Offers Drug for Treatment of Chronic Lymphatic Leukemia
(Sept 7, 2006)
|
|
|
